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Abstract
Objective To determine whether treatment with agonists of glucagon-like
peptide-1 receptor (GLP-1R) result in weight loss in overweight or obese
patients with or without type 2 diabetes mellitus.
Design Systematic review with meta-analyses.
Data sources Electronic searches (Cochrane Library, Medline, Embase,
and Web of Science) and manual searches (up to May 2011).
Review methods Randomised controlled trials of adult participants with
a body mass index of 25 or higher; with or without type 2 diabetes
mellitus; and who received exenatide twice daily, exenatide once weekly,
or liraglutide once daily at clinically relevant doses for at least 20 weeks.
Control interventions assessed were placebo, oral antidiabetic drugs,
or insulin.
Data extraction Three authors independently extracted data. We used
random effects models for the primary meta-analyses. We also did
subgroup, sensitivity, regression, and sequential analyses to evaluate
sources of intertrial heterogeneity, bias, and the robustness of results
after adjusting for multiple testing and random errors.
Results 25 trials were included in the analysis. GLP-1R agonist groups
achieved a greater weight loss than control groups (weighted mean
difference −2.9 kg, 95% confidence interval –3.6 to –2.2; 21 trials, 6411
participants). We found evidence of intertrial heterogeneity, but no
evidence of bias or small study effects in regression analyses. The results
were confirmed in sequential analyses. We recorded weight loss in the
GLP-1R agonist groups for patients without diabetes (–3.2 kg, –4.3 to
–2.1; three trials) as well as patients with diabetes (–2.8 kg, –3.4 to –2.3;
18 trials). In the overall analysis, GLP-1R agonists had beneficial effects
on systolic and diastolic blood pressure, plasma concentrations of
cholesterol, and glycaemic control, but did not have a significant effect
on plasma concentrations of liver enzymes. GLP-1R agonists were
associated with nausea, diarrhoea, and vomiting, but not with
hypoglycaemia.
Conclusions The present review provides evidence that treatment with
GLP-1R agonists leads to weight loss in overweight or obese patients
with or without type 2 diabetes mellitus.
Introduction
In the United States, more than two thirds of the population is
overweight (body mass index 25-29.9) or obese (body mass
index ≥30). This proportion is smaller in Europe, but continues
to increase.
1 The World Health Organization estimates that 1.5
billion adults worldwide are overweight and 500 million are
obese. Almost three million adults die each year as a result of
beingoverweightorobese.Anestimated44%oftheburdenfor
diabetes has been attributed to these weight problems, as well
as 23% and 7-41% of the burdens for ischaemic heart disease
and specific cancers, respectively.
2
Weight loss is not easily accomplished or maintained.
Meta-analyses of clinical trials on non-pharmacological
strategies for weight reduction have reported 1-6 kg losses that
havebeendifficulttomaintain.
3-5Meta-analysesofsibutramine
and orlistat trials report average weight reductions of 3 kg to 5
kg, but some of the included trials had attrition rates of up to
50% that were possibly due to adverse events, suggesting that
the interventions could be less effective in clinical practice.
6-8
Meta-analyses have found that bariatric surgery reduces long
term mortality in obese patients,
9 10 but the safety risks and the
costs of this intervention limit the use for large patient
populations.
The risk of developing diabetes escalates with the degree of
excessbodyweight,increasingthreefoldwithabodymassindex
of 25.0 to 29.9, and 20-fold with an index of 35 and higher
compared with a healthy index of 18.5-24.9.
11 The difficulties
encounteredinthemanagementoftype2diabetesareindicated
by the low proportion (<50%) of patients treated to therapeutic
goals.
12 13 Problems in treatment management might be related
to shortcomings with the currently available drugs, including
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RESEARCHbodyweight increase (thiazolidinediones, sulphonylureas, and
insulin), hypoglycaemia (sulphonylureas, repaglinides, and
insulin), and gastrointestinal side effects (metformin and alpha
glucosidase inhibitors).
14
Glucagon-like peptide-1 (GLP-1) is a gut hormone that is
secretedfromtheintestineinresponsetomealingestion.GLP-1
based therapy was recently introduced as a new treatment for
patients with type 2 diabetes mellitus. Treatment with GLP-1
enhances the endogenous secretion of insulin induced by meal
ingestion and inhibits glucagon secretion, thereby improving
glucose homoeostasis. Notably, it also suppresses food intake
and appetite. Trials of patients with type 2 diabetes suggest that
agonists of GLP-1 receptor (GLP-1R) have beneficial effects
on metabolic regulation and could lead to weight loss. We did
a systematic review and meta-analysis to provide an up to date
overview of the beneficial and harmful effects of GLP-1R





versus placebo, no intervention, or other antidiabetic
interventions for weight loss in overweight patients with or
without type 2 diabetes mellitus. Secondary outcome measures
includedchangesinsystolicanddiastolicbloodpressure,plasma
concentrations of liver enzymes (alanine aminotransferase and
alkaline phosphatase activity), total cholesterol, and adverse
events. For patients with type 2 diabetes, we also assessed
markers of glycaemic control: fasting plasma glucose, glycated
haemoglobin (percentage of HbA1c), and the proportion of
patients achieving a target level of HbA1c less than 7%.
Search strategy for identification of trials
Eligibletrialswereidentifiedbyelectronicandmanualsearches.
We planned to include trials irrespective of publication status
or quality of bias control. For the electronic searches, we
reviewed the Cochrane Library, Medline, Embase, and Web of
Science. We did not make any restrictions regarding the trials’
languageoryearofpublication.ThelastsearchupdatewasMay
2011.
In the Cochrane Library, we used the search strategy for
“liraglutide”, “glucagon-like peptide-1”, or “exenatide”. For
the remaining databases, the search terms included
“glucagon-like peptide-1”, “liraglutide”, or “exenatide”; and
“RandomisedControlledTrial”or“random”.Thesetermswere
adjusted to fit the requirements specified in each database. We
searched trial registries using the search portal of the WHO
International Clinical Trial Registry Platform (www.who.int/
ictrp/search/en/).
The reference lists of relevant papers were also reviewed
manually. We originally planned to obtain unpublished data
fromincludedtrialsthroughemailcorrespondencewiththefirst
authorsofincludedpublicationsandpharmaceuticalcompanies.
Since all trials turned out to be industry funded, we retrieved
all additional data by correspondence with pharmaceutical
companies.
Review methods and selection criteria
Eligibletrialswerelistedandtheinclusioncriteriawereassessed
independently by all authors. Excluded trials were listed with
the reason for exclusion. Three authors (TV, MC, and LLG)
extracted data independently. Disagreements were resolved
through discussion. Randomised controlled trials were eligible
irrespective of their publication status. We included trials of
adult patients with or without type 2 diabetes and who had a
body mass index of 25 or more. The GLP-1R agonists assessed
were exenatide given twice daily, exenatide given once weekly
(as a long acting release), and liraglutide given once daily. The
control groups were placebo, no intervention, or antidiabetic
drugs. If trials included more than one control group, we
included data from the most weight neutral intervention (for
example, placebo instead of insulin). We also included
randomisedcomparisonsbetweenexenatideandliraglutide.To
undertake a review that applied to clinical practice, we only
includedtrialswithadurationofatleast20weeksthatassessed
clinically relevant doses of at least 10 µg/day for exenatide (5
µg twice daily), 2 mg/week for exenatide once weekly, and 1.2
mg/day for liraglutide once daily.
Assessment of risk of bias
Based on previous evidence, we classed the randomisation
methods of selected trials as the primary measure of bias
control.
16 We assessed randomisation methods by how the
allocationsequencewasgenerated(classedasadequateifbased
on a table of random numbers, computer generated random
numbers,orsimilar)andconcealed(classedasadequateifbased
on central randomisation, identically coded drug containers,
serially numbered opaque sealed envelopes, or similar).
We also extracted information on the following:
(1)Blinding(whetherthetrialwasdescribedasdoubleblind
or single blind, the method of blinding; whether patients,
investigators, outcome assessors, or other individuals
participating in the trial were blinded; and whether the
adequacy of blinding was assessed)
(2)Riskofattritionbias(numbersofandreasonsfordropouts
and withdrawals, and whether all patients were accounted
for in the report and analysis of the trial)
(3) Whether the primary outcome measure was defined and
reported
(4) Whether sample size calculations were done
(5) Whether the preset sample size was achieved
(6) For trials terminated prematurely, whether this
termination was based on predefined criteria
Statistical analysis
We did data analyses using Stata version 11 (Stata Corp, TX,
USA) and Trial Sequential Analysis 2007 (Copenhagen Trial
Unit, Copenhagen, Denmark). We used random effects models
for the primary analyses because we expected clinical
heterogeneity between trials (owing to different criteria for
patient inclusion and different intervention regimens). Results
of the meta-analyses were expressed as weighted mean
differences for continuous outcomes and relative risks for
dichotomous outcomes, both with 95% confidence intervals,
and with tau
2 values and P values as markers of intertrial
heterogeneity. For dichotomous outcomes, we calculated the
number needed to treat if the outcome measure was significant
(that is, the confidence interval did not cross 1). For trials
assessingmorethanonedoseofGLP-1Ragonist,datafromthe
group allocated to receive the highest dose were included in the
primary meta-analysis. We repeated the meta-analysis for the
lower doses.
We also repeated the meta-analyses using fixed effects models,
to test the robustness of the results after attributing less weight
to small trials. We reported the results of the fixed effects
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effects models. Regression analysis of funnel plot asymmetry
allowed us to assess any evidence of publication bias and small
study effects (Egger’s test). Subgroup analysis examined the
intervention effects in trials on different participants (with or
without diabetes) and different interventions (that is, exenatide
twice daily, exenatide once weekly, or liraglutide once daily).
We did random effects meta-regression to investigate whether
body mass index or trial duration could predict the size of the
estimatedinterventioneffects.Wealsousedsequentialanalysis
toassesstherobustnessoftheresultsafteradjustingformultiple
comparisons (with repeated cumulative meta-analyses). The
sequential analysis was done with alpha set to 5%, power to
80%, and a model based heterogeneity correction of 99%. The
intervention effects entered in the sequential analysis were
selected on the basis of the observed results.
Results
Weidentified694potentiallyeligiblereferencesusingtheinitial
searches (fig 1⇓). After excluding duplicates and clearly
irrelevant references, we retrieved 101 relevant references. Of
thesereferences,76describedsubgroupanalysesofrandomised
trials, were non-randomised follow-up studies of trials, or did
not assess exenatide or liraglutide at the duration or dose
specifiedinourinclusioncriteria.Theremaining25randomised
controlled trials fulfilled our inclusion criteria.
17-41 We received
additional data that were not described in the published reports
ontrialmethodsandoutcomemeasuresfrom17oftheincluded
trials.
17-19 22 24-26 30-37 39 40
All the included trials were published as full paper articles
betweenJanuary2004andMay2011(table1⇓).Thetrialswere
multicentred (mean number of clinical sites 68) and
multinational.MosttrialsweredoneintheUSandEurope.The
duration of individual trials ranged from 20 to 52 weeks. Three
trials included patients without diabetes
17-19 in the remaining
trials, all patients were diagnosed with type 2 diabetes.
Thepatientcharacteristicsatbaselineandthediagnosticcriteria
for type 2 diabetes were very similar across trials. Mean body
mass index ranged from 29 to 41, and mean weight from 82 to
111 kg, for both the GLP-1R agonist groups and the control
groups.Forpatientswithtype2diabetes,themeanconcentration
of fasting plasma glucose at baseline ranged from 8.0 to 11.7
mmol/L for GLP-1R agonist groups, and from 8.2 to 11.2
mmol/L for control groups. Mean values of HbA1c at baseline
ranged from 7.6% to 10.4% for GLP-1R agonists and 7.4% to
10.3% for controls, respectively.
The included trials assessed exenatide twice daily (n=13
trials),
18-21 24 25 27-29 33 34 36 38 liraglutide (n=8),
17 26 32 35 37 39-41 and
exenatideonceweekly(n=4;table1).
22 23 30 31Threetrialsdirectly
compared exenatide twice daily with liraglutide or with
exenatide once weekly.
23 26 31. The dose of liraglutide given in
most trials was 1.2 or 1.8 mg/day; one trial of obese individuals
without diabetes also used doses of 2.4 and 3 mg/day.
17 The
doses of exenatide used were 10 to 20 µg/day or 2 mg/week.
The GLP-1R agonists were given as subcutaneous injections
once daily for liraglutide, and twice daily and once weekly for
exenatide.Thecontrolgroupsreceivedplacebo,thirdgeneration
sulphonylurea compounds, insulin, dipeptidyl peptidase 4
inhibitors,thiazolidinediones,ormetformin.Intrialsofpatients
with type 2 diabetes, cointerventions given to the intervention
and control group included metformin, sulphonylurea
compounds, or thiazolidinediones.
Quality of bias control
Allocation sequence generation and allocation concealment
were adequate in all trials. None of the trials found differences
in the baseline characteristics of participants between the
GLP-1Ragonistandcontrolgroups.Thirteentrialsweredouble
blind, with masking of both patients and investigators. None of
the included trials reported the success of blinding. All trials
reportedclinicallyrelevantoutcomemeasures,providedaclear
description of losses to follow-up, accounted for patients with
missing data in the analyses, and undertook sample size
calculations. None of the trials were terminated prematurely.
We found no evidence of reporting bias when comparing
published trial protocols with subsequent trial reports.
Body weight
All trials reported weight loss. We did a random effects
meta-analysis including 3395 participants randomly assigned
to GLP-1R agonists and 3016 assigned to the control groups,
from 21 trials (fig 2⇓). The control groups in the analysis
received placebo, oral antidiabetic drugs, or insulin (table 1).
The mean reduction in body weight achieved with the highest
dose of GLP-1R agonists ranged from –7.2 to –0.2 kg. The
weighted mean change in body weight was larger for patients
intheGLP-1Ragonistgroupthanforthoseinthecontrolgroup
(–2.9 kg, 95% confidence interval –3.6 to –2.2). We found
evidence of intertrial heterogeneity in the analysis (tau
2=2.4,
P<0.01). Subgroup analyses showed a greater weight loss after
treatment with the highest doses of GLP-1R agonists. We saw
a weight reduction in patients without diabetes (–3.2 kg, –4.3
to–2.1)aswellasinthosewithdiabetes(–2.8kg,–3.4to–2.3).
A repeat of the initial meta-analyses with fixed effects models
confirmed the primary meta-analysis. The regression analysis
did not show any clear evidence of bias or small study effects
(Egger’s test, P>0.1 for all analyses). We saw no difference in
bodyweight changes for patients assigned liraglutide versus
exenatide twice daily (−0.4 kg, 95% confidence interval –1.3
to 0.6), or for those assigned exenatide as a long acting release
versus exenatide twice daily (–0.6 kg, –1.5 to 0.3). Subgroup
analysesshowedaweightreductionintrialsassessingexenatide
twicedaily(–2.8kg,–2.9to–2.7),exenatideonceweekly(–2.8
kg, –5.2 to –0.3), and liraglutide (–2.2 kg, –3.5 to –0.9). We
alsosawaweightreductionfortrialsinwhichthecontrolgroup
received placebo (–1.9 kg, –2.9 to –0.9; 10 trials), insulin (–4.8
kg, –5.1 to –4.5; six trials), oral antidiabetic drugs including
metformin or sulphonylurea compounds (–3.0 kg, –4.9 to –1.2;
three trials), and dipeptidyl peptidase 4 inhibitors (–2.0 kg, –2.9
to –1.1; two trials). Random effects meta-regression of the
primary meta-analysis found that body mass index at baseline
and trial duration did not predict the size of the estimated
intervention or explain intertrial heterogeneity (P=0.293 and
P=0.284, respectively).
We did the sequential analysis based on the results of the
primary meta-analysis, including the highest dose of GLP-1R
agonistsassessedcomparedwithcontrols.Theanalysisshowed
that the cumulative Z curve crossed the monitoring boundary
after the seventh trial, which suggested that we had sufficient
evidence (that is, the optimal information size was reached) to
confirmtheinterventioneffectafteradjustingformultipletesting
and random error.
Blood pressure, cholesterol, and liver
enzymes
Random effects meta-analyses found that the GLP-1R agonists
reducedsystolicbloodpressure(fig3⇓),diastolicbloodpressure
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RESEARCH(fig4⇓),andtotalcholesterolconcentrations(fig5⇓).Wefound
noevidenceofbiasfortheanalysisofsystolicordiastolicblood
pressure (Egger’s test, P=0.500 and P=0.107, respectively) or
cholesterol (P=0.081).
We retrieved data for liver enzymes from 17 trials. However,
sincethesedatawerereportedinconsistently,wewereonlyable
to include data from 12 of these trials (fig 6⇓). The overall
difference in concentrations of alanine aminotransferase was
significant in the fixed effects meta-analysis, but not in the
random effects analysis (–1.0 U/L, 95% confidence interval
–2.5 to 0.6). In subgroup analyses, alanine aminotransferase
concentrations decreased after treatment with liraglutide (–2.2
U/L, –3.6 to –0.9) but not with exenatide (0.7 U/L, –1.1 to 2.4).
GLP-1R agonists did not have a clear effect on alkaline
phosphataseconcentrationsaftertreatmentintheoverallanalysis
(1.1 U/L, –0.6 to 2.8) or in separate analyses of liraglutide or
exenatide. We also did not see any evidence of small study
effects in regression analyses (Egger’s test; alanine
aminotransferase, P=0.371; alkaline phosphatase, P=0.123).
Glycaemic control (patients with type 2
diabetes)
In patients with type 2 diabetes, the highest doses of GLP-1R
agonistsreducedHbA1cpercentagecomparedwithplacebo,oral
antidiabetic drugs, or insulin (fig 7⇓; Egger’s test, P=0.764). In
the random effects analysis, we saw no clear difference in the
changeinmeanconcentrationoffastingbloodglucosebetween
the highest doses of GLP-1R agonists and controls (–0.51




model, we found that GLP-1R agonists were associated with a
greater reduction in concentrations of fasting glucose than
controls (–1.32 mmol/L, –1.35 to –1.29).
The proportion of participants who achieved the haemoglobin
target (HbA1c <7%) was higher in the GLP-1R agonists group
than in controls (relative risk 1.98, 95% confidence interval
1.46 to 2.70; tau
2=0.28; χ
2 test, P=0.10). The corresponding
number needed to treat was six patients (four to 10 patients).
Egger’s test found evidence of small study effects (P=0.001).
Repeating the primary analysis with a fixed effects model
confirmed the overall results (relative risk 1.75, 1.59 to 1.92).
WefoundsimilarresultsfortrialsusingalowerdoseofGLP-1R
agonist(thatis,liraglutide1.2mg/dayandexenatide10µg/day).
When comparing the highest dose with the lowest dose of
GLP-1Ragonistsassessedintheindividualtrials,randomeffects
meta-analysis showed that the highest doses were associated
with a greater reduction in mean HbA1c (–0.10%, –0.17% to
–0.02%) and increased the proportion of patients who achieved
the target HbA1c (relative risk 1.14, 1.03 to 1.27). We saw no
difference between the two highest and lowest doses when
analysingthemeanreductioninfastingbloodglucose(weighted
meandifference–0.14mmol/L,–0.31to0.03).Wesawasimilar
result after repeating the meta-analyses with fixed effects
models.
Adverse events
The trials registered several adverse events (table 2⇓). Overall,
GLP-1R agonists did not increase the number of patients who
withdrew or dropped out. The most frequent adverse events
werehypoglycaemiaandgastrointestinaladverseevents(nausea,
diarrhoea,andvomiting).Adverseeventsbecamemorefrequent
with increasing doses. We found few serious adverse events
(such as major episodes of hypoglycaemia).
Discussion
The present meta-analyses include data from randomised
controlled trials assessing clinically relevant doses of GLP-1R
agonists given for at least 20 weeks. The results indicate that
treatment with GLP-1R agonists help reduce body weight in
patients who are overweight or obese. Three of the included
trialsassessedtheeffectofGLP-1Ragonistsonpatientswithout
type 2 diabetes and 22 assessed patients with type 2 diabetes.
GLP-1R agonists also had beneficial effects on systolic and
diastolic blood pressure. In subgroup and sensitivity analyses,
the liver enzyme activity was lower in the GLP-1R agonist
groups than in the control groups. However, the overall effect
ofGLP-1Ragonistsonliverenzymeswasnotclear.Forpatients
with type 2 diabetes, GLP-1R agonists improved glycaemic
control (as assessed by HbA1c percentage and fasting plasma
glucose) and increased the proportion of patients who achieved
the target haemoglobin.
GLP-1R agonists were associated with several adverse events.
Gastrointestinal side effects (such as nausea, vomiting, and
diarrhoea)werecommon,butdidnotseemtoaffectthenumber
of losses to follow-up. These findings concur with recent
evidence showing that the overall patient satisfaction with
GLP-1R agonist treatment is relatively high.
42
In patients with type 2 diabetes, improved glycaemic control is
often associated with increased body weight.
43 We found that
participants without diabetes achieved greater reductions in
body weight than those with diabetes. Our results suggest that
treatment with GLP-1R agonists are an effective intervention
for participants who are overweight, irrespective of whether
they have diabetes. GLP-1R agonists could be especially
relevant for patients with hypertension, raised cholesterol, or
otherconditionsinthemetabolicsyndrome.However,additional
trials investigating the effect of comorbidities (such as
cardiovascular diseases) are still warranted.
In developed countries, obesity increases mortality and
morbidity as well as the frequency of type 2 diabetes,
hypertension, and non-alcoholic fatty liver disease. Obesity,
particularly with an excess of visceral or ectopic fat, is an
independent risk factor for heart disease and several studies
suggest that obesity has detrimental effects on complications
to infectious diseases,
44 quality of life and depression,
45 and
cancer related mortality.
46 These diseases have an important
impact on the individuals affected, and the management of
complications to obesity puts an increasing strain on the
healthcare systems. A recent German study found that the cost
associatedwithobesityisapparentevenfromchildhood.
47Since
nearly 50 million children under the age of 5 years are
overweight,
2 we are facing a huge medical, as well as financial,
challenge worldwide. Accordingly, identification of effective
interventions for weight reductions is crucial. The costs with
interventions that lead to lasting weight reduction should be
considered in relation to those with the treatment of
complications to obesity.
In 2005, the US Food and Drug Administration approved the
first long acting stable GLP-1R agonist. Two products are
currently available on the market: exenatide (Byetta; Eli Lilly)
and liraglutide (Victoza; Novo Nordisk). Both drugs are
injectable medications that can be used in combination with
oral antidiabetic drugs such as metformin, thiazolidinediones,
or sulphonylurea compounds. The treatments are approved for
patients with type 2 diabetes who have not achieved adequate
glycaemiccontrolaftertreatmentwithconventionalantidiabetic
interventions. Exenatide treatment is initiated at a 5 µg dose
given twice daily for at least one month to improve tolerability.
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µg twice daily to improve glycaemic control.
48
In October 2011, exenatide as a once weekly injection
(Bydureon; Eli Lilly) reached the European market for the
treatment of type 2 diabetes, with similar indications as for
exenatide twice daily and liraglutide. The starting dose of
exenatide once weekly is 2 mg/week with no need for titration.
The starting dose of liraglutide is 0.6 mg/day; after one week,
the daily dose is increased to 1.2 mg, based on the clinical







These doses seemed to further increase not only the achieved
bodyweightloss,butalsothenumberofgastrointestinaladverse
events.
17 None of the remaining trials assessed equally high
doses.
Patients with obesity and type 2 diabetes have an increased risk
of developing non-alcoholic fatty liver disease.
50 This disease
could have a benign course, although it progresses to
non-alcoholic steatohepatitis in about 20-30% of patients.
Although histological markers remain the best method for
assessing the severity of fatty liver disease, liver enzymes are
associated with the disease activity in the early stages of
non-alcoholic steatohepatitis. We found no clear effect of
GLP-1R agonists on liver enzyme activity. However, since we
didnotanalysehistologicalchanges,additionaltrialsareneeded
to investigate the effects of GLP-1R agonists in participants
with overweight and non-alcoholic fatty liver disease.
Strengths and limitations of the findings
Unlike previous reviews, we were able to gather data for
outcomes that were not described in the published
reports.
17 19 22 24-26 30-37 39 40 Outcome measures are less likely to
be described in published reports if the result is not significant.
Therefore, the retrieval of unpublished outcome data could
reduce the risk of reporting bias (that is, selective reporting of
outcomes with a positive result). The present review also
differed from previous reviews by the inclusion of patients
without type 2 diabetes mellitus. Although the non-specific
inclusion criteria increased intertrial heterogeneity, they also
improved the external validity of our findings. Furthermore, to
achieve and maintain clinically relevant weight loss, we only
included trials that followed participants for a sufficient period
(20 weeks or more).
Inadequate randomisation and attrition bias could lead to
overestimated benefits of an intervention. None of the included
trials had deficiencies in the reported randomisation methods
and all accounted for the intention to treat population in their
results and analyses. These aspects support the internal validity
ofourfindings.Sinceweonlyincludedtrialsthatusedclinically
relevant doses given for clinically relevant treatment periods,
theresultscanbeextrapolatedtoclinicalpractice.Accordingly,
the present review can help evidence based practitioners
determine the size of the treatment benefit.
All the included trials received industry funding. Previous
evidence and clinical examples have described that financial
interests could lead to bias in intervention comparisons.
16 On
the other hand, funding could be associated with adequate
control of bias.
51 Furthermore, in a large cohort of randomised
trials,industryfundingwasassociatedwithmorepositiveauthor
conclusions, but not with the quantitative results of the trials.
52
Sincewedidnotidentifytrialswithoutfunding,wewereunable
to make subgroup analyses to explore the potential effect of
competing interests. We did, however, undertake rigorous
assessments of the quality of included trials. None of our
analysesshowedanyevidenceofselection,assessment,attrition,
or outcome reporting bias. These analyses support the validity
of our results.
Conclusions and clinical implications
Participants who are overweight are likely to develop type 2
diabetes, hypertension, hypercholesterolaemia, liver disease,
and eventually cardiovascular disease. Accordingly, these
participants have a considerably elevated risk of morbidity and
mortality. Traditional treatments for obesity are, unfortunately,
often short lived and consequently not especially effective.
Current treatments for patients with type 2 diabetes are
associatedwithshortcomings(weightgain,hypoglycaemia,and
other side effects) that limit the number of patients reaching
acceptabletherapeuticgoals.Thepresentmeta-analysisprovides
convincingevidencethatGLP-1Ragonists,whengiventoobese
patients with or without diabetes, results in clinically relevant
beneficial effects on body weight. Additional beneficial effects
on blood pressure and total cholesterol might also be achieved.
The intervention should be considered in patients with diabetes
who are obese or overweight. Further studies are needed to
elucidate the effects of GLP-1R agonists in the treatment of
obese patients without diabetes.
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RESEARCHTables
Table 1| Characteristics of included trials
Main inclusion criteria Duration (weeks) Intervention Patients (n) Year Trial
Obesity 24 Liraglutide; orlistate; placebo 371 2009 Astrup
17
Obesity 24 Exenatide; metformin; exenatide and metformin 60 2008 Elkind-Hirsch
18
Obesity 24 Exenatide; placebo 163 2010 Rosenstock
19
Type 2 diabetes 24 Exenatide; placebo 194 2010 Apovian
20
Type 2 diabetes 24 Exenatide; insulin 372 2009 Bergenstal
21
Type 2 diabetes 26 Exenatide; sitagliptin; pioglitazone 491 2010 Bergenstal
22
Type 2 diabetes 24 Exenatide once weekly; exenatide twice daily 252 2011 Blevins
23
Type 2 diabetes 52 Exenatide; insulin glargine 69 2009 Bunck
24
Type 2 diabetes 30 Exenatide; placebo 377 2004 Buse
25
Type 2 diabetes 26 Liraglutide; exenatide 464 2009 Buse
26
Type 2 diabetes 20 Exenatide; insulin 49 2007 Davis
27
Type 2 diabetes 20 Exenatide; rosiglitazone 137 2010 DeFronzo
28
Type 2 diabetes 52 Exenatide; glibenclamide 128 2010 Derosa
29
Type 2 diabetes 26 Exenatide; insulin glargine 456 2010 Diamant
30
Type 2 diabetes 30 Exenatide once weekly; exenatide twice daily 303 2008 Drucker
31
Type 2 diabetes 52 Liraglutide; glimepiride 746 2009 Garber
32
Type 2 diabetes 26 Exenatide; insulin glargine 551 2005 Heine
33
Type 2 diabetes 30 Exenatide; placebo 733 2005 Kendall
34
Type 2 diabetes 26 Liraglutide; rosiglitazone; placebo 1041 2009 Marre
35
Type 2 diabetes 24 Exenatide; placebo 232 2008 Moretto
36
Type 2 diabetes 53 Exenatide; insulin 501 2007 Nauck
37
Type 2 diabetes 26 Liraglutide; glimepiride; placebo 1091 2009 Nauck
38
Type 2 diabetes 26 Liraglutide; sitagliptin 665 2010 Pratley
39
Type 2 diabetes 26 Liraglutide; insulin glargine; placebo 581 2009 Russell-Jones
40
Type 2 diabetes 26 Liraglutide; placebo, metformin, and rosiglitazone 533 2009 Zinman
41
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RESEARCHTable 2| Adverse events in randomised controlled trials, by specific comparisons
Relative risk (95% CI) Comparator group (n/N) Adverse event
2 1
High dose GLP-1R agonists v control interventions*†
0.85 (0.71 to 1.0) 616/2768 578/3142 Withdrawal
0.98 (0.60 to 1.59) 342 (16)/2036 341 (10)/2281 Hypoglycaemia (major episodes)
4.33 (3.16 to 5.94) 219/2556 935/2845 Nausea
2.91 (1.93 to 4.39) 100/2245 277/2494 Vomiting
2.19 (1.79 to 2.68) 127/2157 305/2411 Diarrhoea
High dose GLP-1R agonists v low dose GLP-1R agonists†‡
0.71(0.60 to 0.85) 423/1658 346/1893 Withdrawal
1.57 (0.65 to 3.81) 119 (0)/1214 168 (0)/1335 Hypoglycaemia (major episodes)
3.96 (2.67 to 5.87) 134/1312 469/1425 Nausea
2.67 (1.47 to 4.84) 69/1312 150/1425 Vomiting
2.35 (1.78 to 3.10) 65/1135 171/1247 Diarrhoea
Low dose GLP-1R agonists v control interventions*‡
0.71 (0.52 to 0.97) 392/1426 332/1665 Withdrawal
1.37 (0.75 to 2.52) 119 (0)/1214 134 (1)/1342 Hypoglycaemia (major episodes)
3.21 (2.18 to 4.72) 136/1426 399/1665 Nausea
2.32 (1.03 to 5.21) 69/1312 131/1437 Vomiting
1.70 (1.27 to 2.28) 65/1135 121/1259 Diarrhoea
*Control interventions: placebo, oral antidiabetic medication, or insulin.
†High doses: 20 µg/day for exenatide; 1.8 mg/day for liraglutide.
‡Low doses: 10 µg/day for exenatide; 1.2 mg/day for liraglutide.
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RESEARCHFigures
Fig 1 Flow chart for identification and selection of included randomised trials
Fig 2 Meta-analysis of change in body weight (kg) in included trials after at least 20 weeks of treatment, using random
effects model
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RESEARCHFig 3 Meta-analysis of change in systolic blood pressure (mm Hg) in included trials after at least 20 weeks of treatment,
using random effects model
Fig 4 Meta-analysis of change in diastolic blood pressure (mm Hg) in included trials after at least 20 weeks of treatment,
using random effects model
Fig 5 Meta-analysis of change in concentration of total cholesterol (mmol/L) in included trials after at least 20 weeks of
treatment, using random effects model
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RESEARCHFig 6 Meta-analysis of change in concentration of alanine aminotransferase (U/L) in included trials after at least 20 weeks
of treatment, using fixed effects model
Fig 7 Meta-analysis of reduction in HbA1c percentage in included trials after at least 20 weeks of treatment, using random
effects model
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